Insulins
PreclinicalSmall molecule
Eli LillyInsulins is one of 80 small molecule programs targeting Acute Pancreatitis. It is currently in Preclinical.
3
Indications
3
Total Trials
0
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
206 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerPreclinical
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
Amidate
PfizerPreclinical
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Adriamycin
PfizerPreclinical
Savaysa
Daiichi SankyoPreclinical
Xifaxan
SSalix
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Pancreatitis1 trial
Incretin-based Drugs and Acute Pancreatitis
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02476760·1,417,914 enrolled
Heart Failure1 trial
Incretin-based Drugs and the Risk of Heart Failure
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02456428·1,499,650 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Insulins. EMBL-EBI & Wellcome Sanger Institute.
- [4]